WHO

C D S

C P E

CEE

GLOBAL PROGRAMME

TO ELIMINATE

LYMPHATIC FILARIASIS



World Health Organization

Annual Report on Lymphatic Filariasis

2 0 0 1

© World Health Organization, 2002

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

WHO

C D S

CPE

CEE

GLOBAL PROGRAMME
TO ELIMINATE
LYMPHATIC FILARIASIS

Annual Report on Lymphatic Filariasis



CONTRIBUTORS

Project Manager: Dr Francesco Rio

Writer: Ms Angela Haden

Additional Writing

Contributions: Dr Mary Alleman
Dr Brian Bagnall

Dr Brian Bagnaii Dr Claudia Baltuariali

Dr Claudio Beltramello Dr Gautam Biswas Dr Ole Christensen Dr Paul Derstine Dr John Ehrenberg

Dr John Ehrenberg Dr Kazuyo Ichimori Dr Mary Ellen Kitler

Dr Vasanthapuram Kumaraswami

Mr Kevin Lyonnette Mr Chris Maddock

Professor David Molyneux

Dr Maria Neira

Dr Nikolai Neuouimine

Dr Kevin Palmer Dr Eric Ottesen Dr Chusak Prasittisuk Dr Frank Richards Dr Francesco Rio

Dr Jean-Baptiste Roungou

Dr Anders Seim

Dr Nana Twum-Danso Dr Sergio Yactayo Mr Andy Wright Dr Nevio Zagaria

Editorial

Contributions: Ms Rosemary Besana

Ms Barbara Campanini

Ms Sandra Doyle Ms Tabinda Faizi Dr Ali Hussein

Designers: Helena Zanelli Creation

Photographs: World Health Organization

Additional copies of this publication are available at no charge from:

CDS Information Resource Centre World Health Organization 1211 Geneva 27, Switzerland

Fax: +41 22 791 42 85 E-mail: cdsdoc@who.int

www.who.int/infectious-disease-news

This publication can be viewed and downloaded from the website of the Global Alliance to Eliminate Lymphatic Filariasis at: http://www.filariasis.org

CONTENTS

Introduction Chapter 1. Understanding the problem The disease Transmission of lymphatic filariasis Clinical forms Global burden WHO's global strategy to eliminate lymphatic filariasis Finding the answers Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research Monitoring PELF and information system	-
The disease Transmission of lymphatic filariasis Clinical forms Global burden WHO's global strategy to eliminate lymphatic filariasis Finding the answers Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	
Transmission of lymphatic filariasis Clinical forms Global burden WHO's global strategy to eliminate lymphatic filariasis Finding the answers Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	
Clinical forms Global burden WHO's global strategy to eliminate lymphatic filariasis Finding the answers Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	5
Global burden WHO's global strategy to eliminate lymphatic filariasis Finding the answers Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	5
WHO's global strategy to eliminate lymphatic filariasis Finding the answers Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	6
Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	
Chapter 2. Supporting the Global Initiative The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	
The start of the global initiative The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	10
The Global Alliance to Eliminate Lymphatic Filariasis The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group 7. Implementing the programme 8. Initial assessment and mapping of LF distribution 9. Mass drug administration 9. Social mobilization and advocacy 9. Preventing and limiting disability 9. Training 9. Research	11
The regionalization process 1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	11
1. African Programme Review Group 2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	11
2. American Programme Review Group 3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	15
3. Eastern Mediterranean Programme Review Group 4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	17
4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	17
4. Mekong-Plus Programme Review Group 5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	17
5. Indian Subcontinent Programme Review Group 6. PacELF Coordination and Review Group Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	
Chapter 3. Implementing the programme Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	
Initial assessment and mapping of LF distribution Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	
Mass drug administration Social mobilization and advocacy Preventing and limiting disability Training Research	19
Social mobilization and advocacy Preventing and limiting disability Training Research	19
Preventing and limiting disability	21
Preventing and limiting disability	25
Training	
Research	29
Activities in regions and countries	
1. African Programme Review Group	
American Programme Review Group	
Eastern Mediterranean Programme Review Group	
4. Mekong-Plus Programme Review Group	
5. Indian Subcontinent Programme Review Group	
6. PacELF Coordination and Review Group	

Chapter 4.	Facing future challenges	. 47
•	Fighting diseases of poverty	. 47
	Comprehensive health planning	. 47
	Collaboration with other programmes	. 48
	Targets for 2002 and beyond	. 49
	Financial resources	. 52
	Ways and means to achieve the targets	. 52
Annexes		
	1. Reports of major international supporters and partners	53
	2. List of lymphatic filariasis-endemic countries and territories by RPRGs	59
	3. Reporting SAEs associated with DEC + albendazole regimens	61
	4. Reporting SAEs associated with the ivermectin + albendazole regimens	67
		73

1

Global Programme to Eliminate Lymphatic Filariasis (GPELF)

PROGRAMME HIGHLIGHTS

2001 – The Programme gains momentum



In the countries

- A total of 26 million people in 22 countries were administered a 2-drug, once-yearly treatment in the second year of mass drug administration (MDA) in 2001, almost a ten-fold increase from the year 2000.
- Eleven countries, whose national plans and requests for donated drugs were reviewed and approved, will implement their national programmes in 2002.
- A total of 44 million albendazole tablets were shipped by GlaxoSmithKline to 26 countries for either the first or a subsequent round of mass drug administration.
- A total of 22 million ivermectin tablets (Mectizan®) were shipped by Merck & Co., Inc. to 8 countries covered by the African and Eastern Mediterranean Programme Review Groups; 15.5 million were for MDA in areas with only lymphatic filariasis (LF) while 6.5 million were for areas where lymphatic filariasis and onchocerciasis are co-endemic.
- Surveys continued in all the regions to map implementation units with LF transmission.

PROGRAMME HIGHLIGHTS



- Four of the six regional programme review groups met for the first time in 2001, and two had their first meeting in January 2002. In these meetings, roles and effective working mechanisms were discussed and new plans and re-applications for drugs were reviewed.
- Four workshops on mapping were conducted
 three in Africa and one for the countries of the Mekong-Plus programme review group.
- Ten participants from India and 12 from other countries in the South-East Asian Region were trained on disability prevention and alleviation in Pondicherry, India.
- Twenty-two programme managers were trained in an interregional workshop for countries in the South-East Asian and Western Pacific Regions in programme planning, implementation, management and monitoring held, in Kuala Lumpur, Malaysia.
- The 3rd PacELF Annual Meeting took place in Nadi, Fiji on 24-29 September 2001 with twenty-eight participants from 17 countries.

At the global level

- The Technical Advisory Group (TAG) met for the second time to discuss the issues of monitoring the safety of mass drug co-administration regimens, verifying the absence of infection and interruption of transmission, preventing and alleviating disability caused by lymphatic filariasis, and the supply and dosage forms of diethylcarbamazine citrate (DEC). On the recommendation of the TAG, the Chairman continued working in close collaboration with the Programme from the second half of 2001. In association with the Secretariat, the current priorities were examined and the topics for discussion by the next TAG identified.
- The process of regionalization of the Programme Review Group was completed. Six regional programme review groups were created, where necessary, based on epidemiological requirements rather than the WHO regional organization.
- As a follow-up to the recommendation of the TAG, the data accumulated from the active surveillance were reviewed with the pharmacovigilance specialist of the TAG. The results indicated that the co-administered regimens were safe for wide-scale use. The reactions were qualitatively and quantitatively similar

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5 30307



